<DOC>
	<DOC>NCT00511849</DOC>
	<brief_summary>The purpose of this study is to test SU011248 (sunitinib) in combination with paclitaxel/carboplatin. This combination regimen will be tested for safety and antitumor activity.</brief_summary>
	<brief_title>Study Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically or cytologically proven diagnosis of any advanced solid malignancy that is not amenable to treatment with curative intent Candidates for treatment with carboplatin and paclitaxel with maximum of 2 prior chemotherapy regimens ECOG performance status 0 or 1 Prior chemotherapy, radiation therapy or surgery within 4 weeks prior to study entry except palliative radiotherapy to nontarget, metastatic lesions Diagnosis of any second malignancy within the past 3 years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>